ADCTcame out with a quarterly loss of $0.59 per share versus the estimate of a loss of $0.97. This compares to loss of $0.58 per share a year ago.
ImmunoGen announced that mirvetuximab, its treatment for patients with platinum-resistant ovarian cancer, performed well in a pivotal SORAYA trial. Mirvetuximab had a confirmed ORR of 32.4%, with a duration of response of 5.9 months in the 106-person trial. The data would be submitted to FDA as party of the agency's BLA process in the first quarter of next year.
Mersana came out with a quarterly loss of $0.63 per share versus the estimate of a loss of $0.58. This compares to loss of $0.33 per share a year ago.
Seagen presented two new vedotin-based ADC programs, SGN-PDL1V and SGN-B7H4V, at SITC. Preclinical data demonstrate promising antitumor activity. Both ADCs are set to enter first-in-human phase 1 studies in 2022.
Alkermes announced that it received notices of partial termination from Janssen relating to two NanoCrystal technology. The terminations impact know-how royalties related to sales of long-acting paliperidone products for schizophrenia. Janssen maintains that it has not utilized the technology, but Alkermes disagrees with Janssen's position.
ImmunityBioannounced the expansion of the company’s cancer vaccine programs to include self-amplifying self-adjuvating RNA, recombinant protein vaccine candidates, and potent adjuvant formulations that enhance the quality, durability and breadth of immune responses to infectious diseases and cancer. When combined with the company’s hAd5 T-cell-based vaccine candidate, the company believes this "mix-and-match" approach will enable a new generation of COVID-19 vaccines.
Nektar came out with a quarterly loss of $0.70 per share versus the estimate of a loss of $0.80. This compares to loss of $0.61 per share a year ago.
Xencor announced that its partner Novartis terminated its ex-US rights to vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia.Xencor will drop the development of the drug altogether as well, saying it has no plans for in-house research. Separately, the company announced Zenas BioPharma has acquired exclusive worldwide rights to develop, manufacture, and commercialize obexelimab.Obexelimab is a potential first-in-class bifunctional antibody that targets CD19 with its variable domain. Zenas will issue a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor's total equity in Zenas would be 15% after Zenas' next round of equity financing. Xencor is also eligible to receive up to $480 million milestone payments.
Allogene incurred a loss of $0.57 per share in third-quarter 2021, wider than the estimate of a loss of $0.56 as well as the year-ago loss of $0.52 per share.
Autolus announced thatBlacstone Life Sciences will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidateobe-cel, as well as next generation product therapies of obe-cel in B-cell malignancies.Blackstone is committing to invest $150 million in product financing to support obe-cel development and Blackstone has also agreed to purchase $100 million of Autolus’ shares in a private placement.
Bellicum reported net income of $1.2 million for 3Q 2021, compared to net loss of $0.9 million in 3Q, 2020.
Mustang announced that it signed license agreement with Leiden University Medical Centre for a first-in-class ex vivo lentiviral gene therapy for the treatment of RAG1 severe combined immunodeficiency.
Shares of Arcus rocketed after Gilead said it's exercising options to three programs in the company's clinical-stage portfolio for payments of $725 million. The programs in question include anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat, treatments for different cancers.
Immutep announced the last patient has been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study. The TACTI-002 study has completed recruitment of patients across all cohorts.
Clovis reported 3Q 2021 net loss of $0.56 per share, wider than the estimate of a loss of $0.48 but narrower than the year-ago loss of $0.89.